TMO
62
2
FLS
67
2
DIS
64
3
QRVO
31
2
ICE
62
7
NOV
54
5
CF
35
2
SRE
54
2
HD
35
4
AME
59
2
EIX
58
2
ITW
59
3
CTSH
44
2
AAPL
71
10
BLK
61
3
PCG
81
-12
WAT
59
4
UA
36
3
BDX
49
-5
O
44
2
TMO
62
2
FLS
67
2
DIS
64
3
QRVO
31
2
ICE
62
7
NOV
54
5
CF
35
2
SRE
54
2
HD
35
4
AME
59
2
EIX
58
2
ITW
59
3
CTSH
44
2
AAPL
71
10
BLK
61
3
PCG
81
-12
WAT
59
4
UA
36
3
BDX
49
-5
O
44
2
Financhill
Back

Lyell Immunopharma 10K Form

Sell
49

LYEL
Lyell Immunopharma

Last Price:
2.36
Seasonality Move:
26.7%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive LYEL News And Ratings

See the #1 stock for the next 7 days that we like better than LYEL

LYEL Financial Statistics

Sales & Book Value

Annual Sales: $130K
Cash Flow: $-40.66M
Price / Cash Flow: 0
Annual Sales: $2.58
Price / Book: 0.92

Profitability

EPS (TTM): -0.93000
Net Income (TTM): $-234.63M
Gross Margin: --
Return on Equity: -31.65%
Return on Assets: -27.94%

Lyell Immunopharma Earnings Forecast

Key Lyell Immunopharma Financial Ratios

  • The Research & Development expenses have been 140,726.92% of Revenue.
  • The Net Earning history of LYEL is -180,486.15% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 1 years.

Lyell Immunopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: LYEL
Website: lyell.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 16.07
Quick Ratio: 15.82

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

LYEL Technical Analysis vs Fundamental Analysis

Sell
49
Lyell Immunopharma (LYEL) is a Sell

Is Lyell Immunopharma a Buy or a Sell?